US/UK/Canada

Share

Pick a time period -

Nanoform’s Clinical Study Indicates Positive Interim Results

Insider information Nanoform Finland Plc January 22[nd], 2021 at 08.10 a.m. Finnish time   Nanoform’s Clinical Study Indicates Positive Interim Results Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced positive interim results from its clinical study. The faster absorption data implies that small particles can indeed be powerful. Nanoform has received interim study results related to its Phase 1, Single-Centre, Part Crossover, Open-Label, Partially-Randomised Study Designed to Evaluate the

Nanoform sets a new near-term business target for 2021

Insider information Nanoform Finland Plc January 4[th], 2021 at 08.10 a.m. Finnish time Nanoform sets a new near-term business target for 2021 Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced a new near-term business target. In 2021 Nanoform targets “at least 12 new non-GMP[1] (pre-clinical) customer projects and at least one new GMP[ ](clinical) customer project”. The company reported 2 non-GMP customer projects in 2019 and 7 non-GMP customer projects in Q1-Q3/2020. Nanoform’s Q4/2020 report is due

First dosing of nanoformed drug successfully accomplished

Press Release Nanoform Finland Plc December 21[st], 2020 at 09.00 a.m. Finnish time First dosing of nanoformed drug successfully accomplished Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced that the first full cohort of twelve healthy volunteers has during the weekend at Quotient Sciences’ facilities in Nottingham, UK, been successfully dosed in the first ever phase 1 human trial of a nanoformed drug candidate using Nanoform’s proprietary CESS[®] technology. Results are expected before the end of Q2/

Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules

Inside information Nanoform Finland Plc December 17, 2020 at 7:15 p.m. Finnish time Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules Helsinki, Finland – Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc, an innovative drug development company, today announced that they have signed a letter of intent to collaborate to seek to enhance nasal drug delivery to the brain of Herantis’ CDNF and xCDNF therapies (Parkinson’s disease) using Nanoform’s proprietary biological

Notification of major shareholdings according to Nanoform’s Articles of Association

PRESS RELEASE Nanoform Finland Plc December 8[th],[ ]2020 06.05 p.m. Finnish time Notification of major shareholdings according to Nanoform’s Articles of Association Helsinki, Finland – Nanoform Finland Plc was on December 7[th], 2020, notified by Handelsbanken Fonder AB that its direct ownership has increased to above 5% of shares and votes. Nanoform Finland Plc is listed on Nasdaq First North Premier Growth Market (Helsinki & Stockholm) and flagging notifications are not mandatory in this listing category. However, according to Nanoform’s Articles of Association, major

Nanoform makes US TV debut in Advancements with Ted Danson (CNBC)

PRESS RELEASE Nanoform Finland Plc December 2[nd],[ ]2020 4 p.m. Finnish time Nanoform makes US TV debut in Advancements with Ted Danson (CNBC) Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, will be featured in an upcoming Advancements episode broadcasting via CNBC on Saturday, December 12 at 2:30 pm (ET). Hosted by Ted Danson, the Advancements series is an information-based educational show focusing on cutting-edge developments in a variety of fields. Its aim is to enlighten the public on how technology and

Nanoform Finland Plc, Interim Report January - September 2020, November 27[th], 2020 at 08:00 a.m. Finnish time

COMPANY RELEASE Nanoform Finland Plc, Interim Report January - September 2020, November 27[th], 2020 at 08:00 a.m. Finnish time Strong momentum continues: first GMP campaign initiated, first dosing in humans to start before year-end, all near-term business targets set out in IPO to be achieved ahead of schedule, new global major pharma client signed, two new PoC projects started, one more non-GMP line commissioned and a new near-term business target introduced: “First Biologics PoC project in 2021”.   7-9/2020 key financials: - Revenue was EUR 159 thousand, during 7-9/2019

Nanoform launches technology for biologics and sets new near-term business target for 2021

Inside information Nanoform Finland Plc November 27[th], 2020 at 07:50 a.m. Finnish time   Nanoform launches technology for biologics and sets new near-term business target for 2021 Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, today announced a proprietary technology that can form biological nanoparticles as small as 50 nm and announced a new near-term business target for 2021 to deliver its first biologics Proof of Concept project for this new technology with a pharmaceutical or biotech partner. As drug

Invitation to presentation of Nanoform’s Q3 Report on November 27

PRESS RELEASE Nanoform Finland Plc November 16, 2020 11:00 a.m. Finnish time   Invitation to presentation of Nanoform’s Q3 Report on November 27 Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, will publish its interim report for the third quarter of 2020 on November 27, 2020, at 08.00 a.m. Helsinki time (07.00 a.m. Stockholm time). The company will hold a conference call and an online presentation on the same day at 15.00 p.m. Helsinki time (14.00 p.m. Stockholm time). Nanoform will be represented by CEO

Nanoform to present at Avanza Börsdag on November 18

PRESS RELEASE Nanoform Finland Plc November 11[th], 2020 11:00 a.m. Finnish time Nanoform to present at Avanza Börsdag on November 18[th] Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, will present at Avanza Börsdag on November 18[th], 2020. The presentation and Q&A session are both in English, starting at 12.00 p.m. Stockholm time (1.00. p.m. Helsinki time). They will be broadcast live as a webcast at: https://financialhearings.com/event/12544. The presentation will also be available on Nanoform’s website after

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Company Announcement October 23[rd], 2020 at 7:00 p.m. Finnish time The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees The Annual General Meeting of Nanoform Finland Plc (“Nanoform”) has on 7 April 2020 authorized the company’s Board of Directors to decide on the issuance of shares as well as the issuance of special rights entitling to shares referred to in Chapter 10 Section 1 of the Finnish Limited Liability Companies Act by one or several decisions. The amount of the shares to be issued pursuant to the authorization and the amount

Nanoform initiates GMP campaign for first-in-human trial of nanoformed drug by year end – ahead of schedule

Inside information Nanoform Finland Plc October 20[th], 2020 at 5:15 p.m. Finnish time Nanoform initiates GMP campaign for first-in-human trial of nanoformed drug by year end – ahead of schedule  Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company will, in the fourth quarter of 2020, start the first ever human trial of a drug candidate nanoformed using Nanoform’s proprietary CESS[®] technology. Dosing will begin before year-end[ ]2020 (previously: in 2021) and results are expected before the end of Q2/2021. The clinical

Nanoform Finland Plc – Manager’s transactions – Goncalo Andrade

Nanoform Finland Plc – Manager’s transactions – Goncalo Andrade Nanoform Finland Plc – Manager’s transactions – September 2, 2020 at 03:00 p.m. Finnish time Manager’s transaction related to Nanoform Finland Plc’s other senior manager Goncalo Andrade’s share subscription with stock options from option program 2/2019. Nanoform Finland Plc - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Goncalo Andrade Position: Other senior manager Issuer: Nanoform Finland Plc LEI: 743700JJO2NU8LBS1592

Share subscriptions based on Nanoform Finland Plc's 2/2019 and 1/2020 Stock Option Programs

COMPANY RELEASE September 2, 2020 at 03:00 p.m. Finnish time                              Share subscriptions based on Nanoform Finland Plc's 2/2019 and 1/2020 Stock Option Programs Between August 29 and August 31, 2020, a total of 16,671 Nanoform Finland Plc’s (the "Company" or "Nanoform") new shares have been subscribed for with the Company's 2/2019 and 1/2020 stock options. The entire subscription price for subscriptions made with the stock options of EUR 22,007.15 will be entered in the Company’s reserve for invested unrestricted equity. The shares subscribed for under the

Resolutions of Nanoform Finland Plc's Extraordinary General Meeting and Board of Directors on September 1, 2020

COMPANY RELEASE September 1, 2020 at 1:00 p.m. Finnish time Resolutions of Nanoform Finland Plc's Extraordinary General Meeting and Board of Directors on September 1, 2020. Remuneration policy Nanoform Finland Plc’s Extraordinary General Meeting, held on September 1, 2020 approved the remuneration policy for the company’s governing bodies. The Board of Directors The Extraordinary General Meeting resolved that the Board of Directors consists of four members. Cynthia Schwalm was elected as a new member of the Board of Directors (the “New Board Member”). Miguel Calado, Albert

NANOFORM FINLAND PLC, 2020 HALF YEAR FINANCIAL REPORT, 28 AUGUST 2020 AT 8:10 AM EEST

COMPANY RELEASE NANOFORM FINLAND PLC, 2020 HALF YEAR FINANCIAL REPORT, 28 AUGUST 2020 AT 8:10 AM EEST Nanoform’s half year financial report January–June 2020: Positive momentum continues to build after successful IPO, near-term business target: “to acquire more new customers in 2020 than in 2019” achieved in July. April–June 2020 in brief: · Revenue grew to EUR 191 thousand, up 28% sequentially from EUR 150 thousand in Q1/2020. · Both the gross margin and gross profit increased sequentially, from 68% and EUR 103 thousand in Q1/2020 to 83% and EUR 159 thousand in Q2/2020,

Nanoform convenes EGM to elect Cynthia Schwalm as board member

COMPANY RELEASE August 6, 2020 9:10 am Helsinki time Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), an innovative nanoparticle medicine enabling company, will convene an extraordinary general meeting (EGM) on September 1, 2020 at 10 am Helsinki time to elect Cynthia Schwalm as a new board member. The notice to the EGM was published simultaneously with this release.Cynthia, a renowned Biotechnology CEO and pharmaceutical leader, began her career as an Oncology and Critical Care Nurse at the Albert Einstein Medical Center & Rutgers University Camden Medical Center, where she

Notice to the extraordinary General Meeting of NANOFORM FINLAND PLC

The shareholders of Nanoform Finland Plc (business ID: 2730572-8) are hereby invited to the Extraordinary General Meeting to be held on 1 September 2020 (EET) at 10:00am at Viikinkaari 4, Helsinki, Finland (Cultivator II, meeting room 105, 1[st] floor). A. Agenda of the General Meeting The following matters will be considered at the Extraordinary General Meeting: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinize the minutes and to supervise the counting of votes 4. Recording the legality of the meeting 5. Recording the

Nanoform’s positive commercial momentum continues

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, NEW ZEALAND, AUSTRALIA, JAPAN, HONG KONG, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.Helsinki, Finland – Nanoform Finland Plc, an innovative nanoparticle medicine enabling company, has continued to see positive commercial momentum since its June 4[th], 2020 initial public offering. Despite the ongoing COVID-19 pandemic the company has been able to show progress by signing two experienced commercialization experts in the U.

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Company Announcement June 25, 2020 at 4:00 p.m. Finnish timeThe Annual General Meeting of Nanoform Finland Plc (“Nanoform”) has on 7 April 2020 authorized the company’s Board of Directors to decide on the issuance of shares as well as the issuance of special rights entitling to shares referred to in Chapter 10 Section 1 of the Finnish Limited Liability Companies Act by one or several decisions. The amount of the shares to be issued pursuant to the authorization and the amount of the shares issued by virtue of the authorization to issue special rights entitling to shares shall not exceed

Nanoform Finland Plc appoints Peter Hänninen as General Counsel

Press ReleaseJune 15, 2020 at 8:00 a.m. Finnish time Nanoform Finland Plc (“Nanoform”) today announced the appointment of Peter Hänninen as General Counsel, effective as of September 1, 2020. In this role, he leads Nanoform’s legal operations, including in-house and external legal affairs, intellectual property rights, corporate and commercial matters, compliance and governance. This is a new position within Nanoform and the General Counsel will report to the CEO. Peter Hänninen joins Nanoform from Borenius Attorneys where his practice focused on a broad range of corporate and

Nanoform Finland Plc – Manager’s transactions – Edward Hæggström

Nanoform Finland Plc – Manager’s transactions – June 10, 2020 at 02:00 p.m. Finnish time Manager’s transaction related to Nanoform Finland Plc’s CEO Edward Hæggström’s sale of certain shares in accordance with prospectus in relation to the initial public offering on June 4, 2020 for which trades settled on June 8, 2020. Nanoform Finland Plc - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Haeggström Edward Position: Chief Executive Officer Issuer: Nanoform Finland Plc LEI: 743700JJO2NU8LBS1592

Nanoform Finland Plc – Manager’s transactions – Albert Hæggström

Nanoform Finland Plc – Manager’s transactions – June 10, 2020 at 02:00 p.m. Finnish time Manager’s transaction related to Nanoform Finland Plc’s CFO and member of the Board of Directors Albert Hæggström’s subscription of shares in relation to the initial public offering on June 4, 2020 for which trades settled on June 8, 2020. Nanoform Finland Plc - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Haeggström Albert Position: Member of the Board/Deputy member Issuer: Nanoform Finland Plc LEI:

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media